Key points are not available for this paper at this time.
A decade after the launch of the FDA Sentinel Initiative, it has matured from a pilot program designed to assess potential drug-safety signals in insurance claims into a core component of the agency’s evolving safety surveillance system.
Platt et al. (Wed,) studied this question.